{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T14:37:42Z","timestamp":1777300662855,"version":"3.51.4"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T00:00:00Z","timestamp":1764979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T00:00:00Z","timestamp":1764979200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Urol Nephrol"],"DOI":"10.1007\/s11255-025-04943-y","type":"journal-article","created":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T16:45:24Z","timestamp":1765039524000},"page":"1613-1623","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Androgen deprivation therapy with apalutamide in the treatment of metastatic castration-sensitive prostate cancer: the systematic review of its effectiveness and applicability for Asian men in the targeted investigational treatment analysis of novel anti-androgen (TITAN) trial"],"prefix":"10.1007","volume":"58","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-3358-1415","authenticated-orcid":false,"given":"Fan","family":"Yang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lei","family":"Feng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenwen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simin","family":"Liang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,12,6]]},"reference":[{"key":"4943_CR1","doi-asserted-by":"publisher","first-page":"2643","DOI":"10.1007\/s11845-023-03303-y","volume":"192","author":"M B\u00f6gemann","year":"2023","unstructured":"B\u00f6gemann M, Facchini G, Bauernhofer T et al (2023) Role of apalutamide in the treatment landscape for patients with advanced prostate cancer: an expert opinion statement of European clinical practice. Ir J Med Sci 192:2643\u20132651","journal-title":"Ir J Med Sci"},{"key":"4943_CR2","doi-asserted-by":"publisher","DOI":"10.1177\/17588359221131525","author":"M Saad","year":"2022","unstructured":"Saad M, Umbas R, Chiong E et al (2022) Efficacy and safety of therapies for advanced prostate cancer in Asia: evidence from a systematic literature review. Ther Adv Med Oncol. https:\/\/doi.org\/10.1177\/17588359221131525","journal-title":"Ther Adv Med Oncol"},{"key":"4943_CR3","doi-asserted-by":"publisher","first-page":"7","DOI":"10.4103\/1477-3163.94025","volume":"11","author":"J Cullen","year":"2012","unstructured":"Cullen J, Elsamanoudi S, Brassell S et al (2012) The burden of prostate cancer in Asian nations. J Carcinog 11:7","journal-title":"J Carcinog"},{"key":"4943_CR4","doi-asserted-by":"publisher","first-page":"31","DOI":"10.21037\/pcm-21-25","volume":"4","author":"Z Wang","year":"2021","unstructured":"Wang Z, Zhou C, Feng X et al (2021) Comparison of cancer incidence and mortality between China and the United states. Precis Cancer Med 4:31\u201331","journal-title":"Precis Cancer Med"},{"key":"4943_CR5","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1038\/s41585-021-00442-8","volume":"18","author":"Y Zhu","year":"2021","unstructured":"Zhu Y, Mo M, Wei Y et al (2021) Epidemiology and genomics of prostate cancer in Asian men. Nat Rev Urol 18:282\u2013301","journal-title":"Nat Rev Urol"},{"key":"4943_CR6","doi-asserted-by":"publisher","DOI":"10.3410\/f.739487650.793592245","author":"C Halloran","year":"2022","unstructured":"Halloran C (2022) Faculty opinions recommendation of global cancer statistics 2020: Globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Fac Opin Post-Publ Peer Rev Biomed Lit. https:\/\/doi.org\/10.3410\/f.739487650.793592245","journal-title":"Fac Opin Post-Publ Peer Rev Biomed Lit"},{"key":"4943_CR7","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1093\/jjco\/hyv096","volume":"45","author":"KC Koo","year":"2015","unstructured":"Koo KC, Lee KS, Chung BH (2015) Urologic cancers in Korea. Jpn J Clin Oncol 45:805\u2013811","journal-title":"Jpn J Clin Oncol"},{"key":"4943_CR8","volume":"28","author":"A Kessel","year":"2021","unstructured":"Kessel A, Kohli M, Swami U (2021) Current management of metastatic castration-sensitive prostate cancer. Cancer Treat Res Commun 28:100384","journal-title":"Cancer Treat Res Commun"},{"key":"4943_CR9","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1097\/us9.0000000000000033","volume":"35","author":"SC Hung","year":"2024","unstructured":"Hung SC, Lin YS, Chang YH et al (2024) Management of patients with advanced prostate cancer: report of the Taiwan advanced prostate cancer consensus conference 2022. Urol Sci 35:169\u2013182","journal-title":"Urol Sci"},{"key":"4943_CR10","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1373\/clinchem.2011.165977","volume":"57","author":"P Saraon","year":"2011","unstructured":"Saraon P, Jarvi K, Diamandis EP (2011) Molecular alterations during the progression of prostate cancer to androgen independence. Clin Chem 57:1366\u20131375","journal-title":"Clin Chem"},{"key":"4943_CR11","doi-asserted-by":"publisher","first-page":"4514","DOI":"10.1200\/jco.2005.23.16_suppl.4514","volume":"23","author":"M Smith","year":"2005","unstructured":"Smith M, Kabbinavar F, Saad F et al (2005) Natural history of rising serum PSA in men with castrate nonmetastatic prostate cancer. J Clin Oncol 23:4514\u20134514","journal-title":"J Clin Oncol"},{"key":"4943_CR12","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1200\/JCO.2017.75.3657","volume":"36","author":"CE Kyriakopoulos","year":"2018","unstructured":"Kyriakopoulos CE, Chen YH, Carducci MA et al (2018) Chemohormonal therapy in metastatic hormone-sensitive prostate cancer: long-term survival analysis of the randomized phase III E3805 CHAARTED trial. J Clin Oncol 36:1080\u20131087","journal-title":"J Clin Oncol"},{"key":"4943_CR13","doi-asserted-by":"publisher","first-page":"S507","DOI":"10.1016\/j.annonc.2020.08.871","volume":"31","author":"ND James","year":"2020","unstructured":"James ND, Rush H, Clarke N et al (2020) Abiraterone acetate plus prednisolone for hormone-naive prostate cancer (PCa): Long-term results from metastatic (M1) patients in the STAMPEDE randomised trial (NCT00268476). Ann Oncol 31:S507\u2013S549","journal-title":"Ann Oncol"},{"key":"4943_CR14","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1016\/S1470-2045(19)30082-8","volume":"20","author":"K Fizazi","year":"2019","unstructured":"Fizazi K, Tran N, Fein L et al (2019) Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial. Lancet Oncol 20:686\u2013700","journal-title":"Lancet Oncol"},{"key":"4943_CR15","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.15_suppl.e19322","author":"N Agarwal","year":"2020","unstructured":"Agarwal N, Mundle S, Dearden L et al (2020) Use and outcomes in men with metastatic castration-sensitive prostate cancer (mCSPC) treated with docetaxel in addition to androgen deprivation therapy (ADT): analysis of real-world data in the United States (US). J Clin Oncol. https:\/\/doi.org\/10.1200\/JCO.2020.38.15_suppl.e19322","journal-title":"J Clin Oncol"},{"key":"4943_CR16","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.15_suppl.e19131","author":"X Ke","year":"2020","unstructured":"Ke X, Lafeuille M-H, Romdhani H et al (2020) Treatment patterns in men with metastatic castration sensitive prostate cancer (mCSPC) in the United States (US). J Clin Oncol. https:\/\/doi.org\/10.1200\/JCO.2020.38.15_suppl.e19131","journal-title":"J Clin Oncol"},{"key":"4943_CR17","doi-asserted-by":"publisher","first-page":"2905","DOI":"10.2217\/fon-2020-0557","volume":"16","author":"CM Dror","year":"2020","unstructured":"Dror CM, Chi KN (2020) Apalutamide for the treatment of metastatic castration-sensitive prostate cancer. Future Oncol 16:2905\u20132916","journal-title":"Future Oncol"},{"key":"4943_CR18","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1016\/j.euo.2024.11.005","volume":"8","author":"M Santoni","year":"2025","unstructured":"Santoni M, B\u00fcttner T, Rescigno P et al (2025) Apalutamide in metastatic castration-sensitive prostate cancer: results from the multicenter real-world ARON-3 study. Eur Urol Oncol 8:444\u2013451","journal-title":"Eur Urol Oncol"},{"key":"4943_CR19","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1080\/13543784.2018.1484107","volume":"27","author":"AE Dellis","year":"2018","unstructured":"Dellis AE, Papatsoris AG (2018) Apalutamide: the established and emerging roles in the treatment of Advanced prostate cancer. Expert Opin Investig Drugs 27:553\u2013559","journal-title":"Expert Opin Investig Drugs"},{"key":"4943_CR20","doi-asserted-by":"publisher","first-page":"591","DOI":"10.2217\/fon-2018-0546","volume":"15","author":"HT Borno","year":"2018","unstructured":"Borno HT, Small EJ (2018) Apalutamide and its use in the treatment of prostate cancer. Future Oncol 15:591\u2013599","journal-title":"Future Oncol"},{"key":"4943_CR21","doi-asserted-by":"publisher","DOI":"10.1358\/dof.2015.40.2.2273388","volume":"40","author":"C Reviriego","year":"2015","unstructured":"Reviriego C (2015) ARN-509. androgen receptor signaling inhibitor, prostate cancer therapy. Drugs Future 40:101","journal-title":"Drugs Future"},{"key":"4943_CR22","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1001\/jamaoncol.2016.1854","volume":"2","author":"DE Spratt","year":"2016","unstructured":"Spratt DE, Chan T, Waldron L et al (2016) Racial\/ethnic disparities in genomic sequencing. JAMA Oncol 2:1070","journal-title":"JAMA Oncol"},{"issue":"9","key":"4943_CR23","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1007\/s40262-020-00881-3","volume":"59","author":"A Van den Bergh","year":"2020","unstructured":"Van den Bergh A, Snoeys J, Zwart De et al (2020) Pharmacokinetic drug\u2013drug interaction of apalutamide, part 2: investigating interaction potential using a physiologically based pharmacokinetic model. Clin Pharmacokinet 59(9):1149\u20131160","journal-title":"Clin Pharmacokinet"},{"key":"4943_CR24","doi-asserted-by":"publisher","first-page":"8391","DOI":"10.2147\/DDDT.S541536","volume":"19","author":"LL Zhu","year":"2025","unstructured":"Zhu LL, Yu LY, Wang YH et al (2025) CYP2C8-mediated drug\u2013drug interactions and the factors influencing the interaction magnitude. Drug Des Dev Ther 19:8391\u20138413","journal-title":"Drug Des Dev Ther"},{"key":"4943_CR25","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1111\/iju.14891","volume":"29","author":"Z Zang","year":"2022","unstructured":"Zang Z, Wang Z, Chiong E (2022) Editorial comment to safety and efficacy of Apalutamide in Japanese patients with metastatic castration\u2010sensitive prostate cancer receiving androgen deprivation therapy: final report for the Japanese subpopulation analysis of the randomized, placebo\u2010controlled, phase III titan study. Int J Urol 29:541\u2013541","journal-title":"Int J Urol"},{"key":"4943_CR26","doi-asserted-by":"publisher","DOI":"10.31222\/osf.io\/jb4dx","author":"MJ Page","year":"2020","unstructured":"Page MJ, McKenzie J, Bossuyt P et al (2020) Updating guidance for reporting systematic reviews: development of the prisma 2020 statement. J clin epidemiol. https:\/\/doi.org\/10.31222\/osf.io\/jb4dx","journal-title":"J clin epidemiol"},{"key":"4943_CR27","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l6890","author":"M Campbell","year":"2020","unstructured":"Campbell M, McKenzie JE, Sowden A et al (2020) Synthesis without meta-analysis (SWIM) in systematic reviews: reporting guideline. BMJ. https:\/\/doi.org\/10.1136\/bmj.l6890","journal-title":"BMJ"},{"key":"4943_CR28","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1056\/NEJMoa1903307","volume":"381","author":"KN Chi","year":"2019","unstructured":"Chi KN, Agarwal N, Biartell A et al (2019) Apalutamide for metastatic, castration-sensitive prostate cancer. N Engl J Med 381:13\u201324","journal-title":"N Engl J Med"},{"key":"4943_CR29","doi-asserted-by":"publisher","first-page":"2294","DOI":"10.1200\/JCO.20.03488","volume":"39","author":"KN Chi","year":"2021","unstructured":"Chi KN, Chowdhury S, Bjartell A et al (2021) Apalutamide in patients with metastatic castration-sensitive prostate cancer: final survival analysis of the randomized, double-blind, phase III TITAN study. J Clin Oncol 39:2294\u20132303","journal-title":"J Clin Oncol"},{"issue":"6","key":"4943_CR30","doi-asserted-by":"publisher","first-page":"653","DOI":"10.4103\/aja202320","volume":"25","author":"BH Chung","year":"2023","unstructured":"Chung BH, Huang J, Uemura H et al (2023) Apalutamide for metastatic castration-sensitive prostate cancer: final analysis of the Asian subpopulation in the Titan trial. Asian J Androl 25(6):653\u2013661","journal-title":"Asian J Androl"},{"key":"4943_CR31","doi-asserted-by":"publisher","first-page":"161","DOI":"10.4103\/aja.aja_64_21","volume":"24","author":"BH Chung","year":"2022","unstructured":"Chung BH, Huang J, Ye ZQ et al (2022) Apalutamide for patients with metastatic castration-sensitive prostate cancer in East Asia: a subgroup analysis of the TITAN trial. Asian J Androl 24:161\u2013166","journal-title":"Asian J Androl"},{"key":"4943_CR32","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/j.annonc.2023.02.009","volume":"34","author":"S Chowdhury","year":"2023","unstructured":"Chowdhury S, Bjartell A, Agarwal N et al (2023) Deep, rapid, and durable prostate-specific antigen decline with apalutamide plus androgen deprivation therapy is associated with longer survival and improved clinical outcomes in TITAN patients with metastatic castration-sensitive prostate cancer. Ann Oncol 34:477\u2013485","journal-title":"Ann Oncol"},{"key":"4943_CR33","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1111\/iju.15615","volume":"32","author":"D Ye","year":"2024","unstructured":"Ye D, Uemura H, Chung BH et al (2024) Prostate\u2010specific antigen kinetics in Asian patients with metastatic castration\u2010sensitive prostate cancer treated with apalutamide in the TITAN trial: a post hoc analysis. Int J Urol 32:164\u2013172","journal-title":"Int J Urol"},{"key":"4943_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2023.113290","volume":"193","author":"AS Merseburger","year":"2023","unstructured":"Merseburger AS, Agarwal N, Bhaumik A et al (2023) Apalutamide plus androgen deprivation therapy in clinical subgroups of patients with metastatic castration-sensitive prostate cancer: a subgroup analysis of the Randomized Clinical TITAN Study. Eur J Cancer 193:113290","journal-title":"Eur J Cancer"},{"key":"4943_CR35","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1016\/S1470-2045(19)30620-5","volume":"20","author":"N Agarwal","year":"2019","unstructured":"Agarwal N, McQuarrie K, Bjartell A et al (2019) Health-related quality of life after apalutamide treatment in patients with metastatic castration-sensitive prostate cancer (TITAN): a randomised, placebo-controlled, phase 3 study. Lancet Oncol 20:1518\u20131530","journal-title":"Lancet Oncol"},{"key":"4943_CR36","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1097\/JU.0000000000001841","volume":"206","author":"N Agarwal","year":"2021","unstructured":"Agarwal N, McQuarrie K, Bjartell A et al (2021) Apalutamide plus androgen deprivation therapy for metastatic castration-sensitive prostate cancer: analysis of pain and fatigue in the phase 3 TITAN study. J Urol 206:914\u2013923","journal-title":"J Urol"},{"key":"4943_CR37","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1159\/000532009","volume":"16","author":"CR Flynn","year":"2023","unstructured":"Flynn CR, Liu SC, Byrne B et al (2023) Apalutamide-induced toxic epidermal necrolysis in a Caucasian patient with metastatic castration-sensitive prostate cancer: a case report and review of the literature. Case Rep Oncol 16:652\u2013661","journal-title":"Case Rep Oncol"},{"issue":"15","key":"4943_CR38","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1056\/NEJMoa1715546","volume":"378","author":"MR Smith","year":"2018","unstructured":"Smith MR, Saad F, Chowdhury S et al (2018) Apalutamide treatment and metastasis-free survival in prostate cancer. N Engl J Med 378(15):1408\u20131418","journal-title":"N Engl J Med"},{"key":"4943_CR39","doi-asserted-by":"publisher","DOI":"10.1186\/s12894-020-00689-0","author":"H Uemura","year":"2020","unstructured":"Uemura H, Koroki Y, Iwaki Y et al (2020) Skin rash following administration of Apalutamide in Japanese patients with advanced prostate cancer: an integrated analysis of the phase 3 Spartan and Titan Studies and a phase 1 open-label study. BMC Urol. https:\/\/doi.org\/10.1186\/s12894-020-00689-0","journal-title":"BMC Urol"},{"key":"4943_CR40","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1002\/cia2.12138","volume":"3","author":"N Sagawa","year":"2020","unstructured":"Sagawa N, Watanabe Y, Mizuno Y et al (2020) A case of toxic epidermal necrolysis associated with Apalutamide administration. J Cutan Immunol Allergy 3:134\u2013135","journal-title":"J Cutan Immunol Allergy"},{"key":"4943_CR41","doi-asserted-by":"publisher","DOI":"10.2340\/actadv.v102.2243","author":"K Osawa","year":"2022","unstructured":"Osawa K, Kiniwa Y, Shimosato Y et al (2022) Toxic epidermal necrolysis caused by Apalutamide: a case report of treatment using etanercept with conventional steroid therapy. Acta Dermato-Venereol. https:\/\/doi.org\/10.2340\/actadv.v102.2243","journal-title":"Acta Dermato-Venereol"},{"key":"4943_CR42","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.18660","author":"YO Hsu","year":"2022","unstructured":"Hsu YO, Hsieh T, Huang P et al (2022) Drug reaction with eosinophilia and systemic symptoms with features resembling Stevens-Johnson syndrome\/toxic epidermal necrolysis related to Apalutamide. J Eur Acad Dermatol Venereol. https:\/\/doi.org\/10.1111\/jdv.18660","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"4943_CR43","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1111\/cod.14024","volume":"86","author":"O Ducharme","year":"2021","unstructured":"Ducharme O, Sanchez\u2010Pena P, Pham\u2010Ledard A et al (2021) The first case of drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome caused by Apalutamide, a novel oral androgen receptor antagonist. Contact Dermatitis 86:313\u2013315","journal-title":"Contact Dermatitis"},{"issue":"6","key":"4943_CR44","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1002\/iju5.12525","volume":"5","author":"T Honda","year":"2022","unstructured":"Honda T, Tohi Y, Kaku Y et al (2022) Acute generalized exanthematous pustulosis during apalutamide treatment in a patient with prostate cancer. IJU Case Rep 5(6):497\u2013500","journal-title":"IJU Case Rep"},{"issue":"5","key":"4943_CR45","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1002\/iju5.12331","volume":"4","author":"Y Tohi","year":"2021","unstructured":"Tohi Y, Kataoka K, Miyai Y et al (2021) Apalutamide-associated skin rash in patients with prostate cancer: histological evaluation by skin biopsy. IJU Case Rep 4(5):299\u2013302","journal-title":"IJU Case Rep"},{"key":"4943_CR46","doi-asserted-by":"publisher","first-page":"e315","DOI":"10.1111\/ijd.15420","volume":"60","author":"Y Kawakami","year":"2021","unstructured":"Kawakami Y, Mitsui M, Takamoto H et al (2021) Apalutamide-induced exanthematous drug eruption displaying spongiotic dermatitis successfully treated with dose reduction. Int J Dermatol 60:e315\u2013e317. https:\/\/doi.org\/10.1111\/ijd.15420","journal-title":"Int J Dermatol"},{"issue":"12","key":"4943_CR47","doi-asserted-by":"publisher","first-page":"1596","DOI":"10.1007\/s10147-019-01526-7","volume":"24","author":"T Tsuchiya","year":"2019","unstructured":"Tsuchiya T, Imanaka K, Iwaki Y et al (2019) An open-label, phase 1 study of androgen receptor antagonist, apalutamide in Japanese patients with metastatic castration-resistant prostate cancer. Int J Clin Oncol 24(12):1596\u20131604","journal-title":"Int J Clin Oncol"}],"container-title":["International Urology and Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-025-04943-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11255-025-04943-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-025-04943-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T13:42:09Z","timestamp":1777297329000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11255-025-04943-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,6]]},"references-count":47,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,5]]}},"alternative-id":["4943"],"URL":"https:\/\/doi.org\/10.1007\/s11255-025-04943-y","relation":{},"ISSN":["1573-2584"],"issn-type":[{"value":"1573-2584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,6]]},"assertion":[{"value":"25 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}